4 – 5 September 2024
Valencia, Spain

The VALUE-Dx project is coming to an end soon, and to mark this momentous occasion, a closing conference will be held on 4 – 5 September. This two-day event will take place in the NH Valencia Center Hotel in Valencia, Spain. It will provide a unique opportunity to look back on the project and discuss our final results, recommendations and outcomes. There will also be ample room to interact and share ideas with invited stakeholders outside of the VALUE-Dx consortium.

You can find the programme below.

If you’re interested, you can attend the sessions virtually as of 4 September! 

Join online

All day

Arrival of delegates

19:00h –
21:30h

Dinner at NH Valencia Center Hotel

08:00h –
08:30h

Welcome coffee

08:30h –
08:45h

Welcoming and objectives of the meeting
– Herman Goossens, University of Antwerp

08:45h –
09:30h

VALUE-Dx Clinical Algorithm: analysis, costing and sustainability
– Evelina Tacconelli, Verona University Hospital
– Anna Gorska, Verona University Hospital
– Simon van der Pol, University Medical Center Groningen

09:30h –
10:45h

User Requirement Specifications and Technical Roadmap: Panel discussion
Chairs:
– Till Bachmann, University of Edinburgh
– Benjamin Hommel, bioMérieux

Panelists:
– Erin Duffy (CARB-X)
– Carly Levine (AMR Action Fund)
– Eva Rennen (BEAM)
– Beverley Isherwood (PACE)
– Joao Madeira (HERA)

10:45h –
11:15h

Coffee break

11:15h –
12:30h

Interoperability networks for AMR clinical research: a gateway to open science
Chairs:
– Frank Leus, University Medical Center Utrecht
– Jean-François Gorse, bioMérieux

  1. Introduction into a common data model
    – Freija Descamps, edenceHealth
  2. Interoperability of AMR data using OMOP: a Proof-of-Concept
    – Jean-François Gorse, bioMérieux
  3. From concept to a sustainable network
    – Marc Padros, University Medical Center Utrecht
    – Mauro Tobin, Software for Health Foundation Ltd
  4. ECRAID-Base and future directions
    – Ankur Krishnan/Priya Shreedhar, Heidelberg University
  5. Questions and discussion

12:30h –
12:45h

Tek-Ang Lim, Scientific Officer and VALUE-Dx Project Officer, Innovative Health
Initiative

12:45h-
13:45h

Lunch

Clinical trial sessions

13:45h-
15:40h

PRUDENCE study results
Chairs:
– Chris Butler, University of Oxford
– Suzanne Emmerich, Abbott

1. Main findings and implications for practice, policy and research
– Chris Butler, University of Oxford

2. What do clinicians and patients say about the opportunities and barriers to the optimal use of POCTs in the community?
– Marta Wanat, University of Oxford

3. Main microbiology findings
– Surbhi Malhotra-Kumar, University of Antwerp

4. Economic evaluation
– Pim van Dorst, University Medical
Center Groningen

5. Lessons learnt in developing a health economic analysis plan (HEAP)
– Laura Flight, NICE

15:40h –
16:10h

Coffee break

16:10h –
17:40h

ADEQUATE study results
Chairs:
– Emmanuel Roilides, University of Thessaloniki
– Florence Allantaz, bioMérieux

1. Main findings and implication implications for practice, policy and research
– Malte Kohns, PENTA Foundation

2. Main microbiology findings
– Surbhi Malhotra-Kumar, University of Antwerp

3. Lessons learned for future diagnostic clinical trials
– Julia Bielicki, PENTA Foundation

4. Economic evaluation
– Fernando Antonanzas, University of La Rioja

19:30h –
22:00h

Dinner in downtown Valencia at Restaurante Gulliver

08:15h –
08:45h

Welcome coffee

08:45h –
09:45h

Health-economic session
Chairs:
– Maarten Postma, University Medical Center Groningen
– Jean-Louis Tissier, bioMérieux

1. HTA, policy Recommendations related to funding, pricing, and procurement to enhance the use of Point-of-Care Tests for CA-LRTI
– Sabine Vogler, Gesundheit Österreich

2. Demonstration of how to use the long-term health economic modeling
– Simon van der Pol, University Medical Center Groningen

3. Transferability of trial- and model-based analyses between countries
– Clazinus Veijer, University Medical Center Groningen

9:45h –
10:50h

Session on external engagement, impact and sustainability
Chairs:
– Tim Jinks, Welcome
– Herman Goossens, University of Antwerp

1. Learnings from the regulatory-HTA-payer External Advisory Panel
– Fatima Salih, NICE
2. Recommendations on the role of rapid diagnostic tests for CA-LRTI and the legacy of VALUE-Dx through ERS and ESCMID
– Murat Akova, ESCMID and Eva Polverino, ERS
3. The future of VALUE-Dx: ERS CRC AMR-Lung
– Chris Butler, University of Oxford

10:50h –
11:20h

Coffee break

11:20h –
12:20h

Final session: panel discussion on the role of rapid diagnostics for CA-LRTI
Moderators:
– Laura Flight, NICE
– Samuel Coenen, University of Antwerp 

Panelists:
– PI PRUDENCE: Chris Butler, University of Oxford
– PI ADEQUATE: Julia Bielicki, PENTA Foundation
– Health economist: Maarten Postma, University Medical Center Groningen.
– HTA representative: Guenka Petrova, Medical University Sofia
– Behavioural scientists: Sibyl Anthierens, University of Antwerp

12:20h-
12:30h

Conclusions and Goodbye
– Herman Goossens, University of Antwerp

12:30h -…

Lunch and return home